Ammonium Chloride → HCID 178488155, 화합물

반응식

[CH3:1][C:2]1[CH:3]=[N:4][C:5]([CH2:11][S+:12]([O-:24])[C:13]2[NH:14][C:15]3[CH:16]=[CH:17][C:18]([O:22][CH3:23])=[CH:19][C:20]=3[N:21]=2)=[C:6]([CH3:10])[C:7]=1[O:8][CH3:9].[Cl-].[Mg+2].[Cl-].[Cl-].[NH4+:29]>N>[CH3:1][C:2]1[CH:3]=[N:4][C:5]([CH2:11][S+:12]([O-:24])[C:13]2[NH:14][C:15]3[CH:16]=[CH:17][C:18]([O:22][CH3:23])=[CH:19][C:20]=3[N:21]=2)=[C:6]([CH3:10])[C:7]=1[O:8][CH3:9].[NH3:29]

참가 물질

실험 절차

In the process of the invention, it is preferred to pre-form a solution of omeprazole in concentrated ammonia, and to add this to a pre-formed aqueous solution of magnesium salt (preferably magnesium chloride) and ammonium salt (preferably ammonium chloride), so that the magnesium ion is in excess during the mixing procedure. However, other orders of addition can be used if the process is conducted carefully, such as mixing the omeprazole, ammonia and ammonium salt first, and adding the magnesium salt to this mixture, or, less desirably, pre-mixing the magnesium salt and ammonium salt, and adding this mixture to pre-formed omeprazole/ammonia solution.